start-ver=1.4 cd-journal=joma no-vol=78 cd-vols= no-issue=3 article-no= start-page=227 end-page=235 dt-received= dt-revised= dt-accepted= dt-pub-year=2024 dt-pub=202406 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effect of Lipopolysaccharide on the Duration of Zolpidem-Induced Loss of Righting Reflex in Mice en-subtitle= kn-subtitle= en-abstract= kn-abstract=Zolpidem, a non-benzodiazepine hypnotic, is primarily used to treat insomnia. In a previous study, pior treatment with non-benzodiazepine receptor agonists was associated with inflammation. The present study aimed to clarify the association between the effects of zolpidem and inflammation in mice treated with lipopolysaccharide (LPS), a known model of inflammation. We assessed the zolpidem-induced loss of righting reflex (LORR) duration 24 h after LPS treatment in mice. Additionally, the expressions of γ-aminobutyric acid (GABA)A receptor subunit and K+-Cl− cotransporter isoform 2 (KCC2) mRNA in the hippocampus and frontal cortex were examined in LPS-treated mice. Pretreatment with LPS was associated with significantly prolonged duration of zolpidem-induced LORR compared to control mice. This effect was significantly attenuated by administering bicuculline, a GABAA receptor antagonist, or flumazenil, a benzodiazepine receptor antagonist, in LPS-treated mice. Compared to controls, LPS-treated mice showed no significant change in the expression of GABAA receptor subunits in the hippocampus or frontal cortex. Bumetanide, an Na+-K+-2Cl− cotransporter isoform 1 blocker, attenuated the extended duration of zolpidem-induced LORR observed in LPS-treated mice. LPS significantly decreased Kcc2 mRNA expression in the hippocampus and the frontal cortex. These findings suggest that inflammation increases zolpidem-induced LORR, possibly through a reduction in KCC2 expression. en-copyright= kn-copyright= en-aut-name=WadaYudai en-aut-sei=Wada en-aut-mei=Yudai kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=UshioSoichiro en-aut-sei=Ushio en-aut-mei=Soichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ZamamiYoshito en-aut-sei=Zamami en-aut-mei=Yoshito kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= affil-num=1 en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=3 en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Clinical Pharmacy, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= en-keyword=lipopolysaccharide kn-keyword=lipopolysaccharide en-keyword=zolpidem kn-keyword=zolpidem en-keyword=GABAA receptor kn-keyword=GABAA receptor en-keyword=K+-Cl− cotransporters kn-keyword=K+-Cl− cotransporters END start-ver=1.4 cd-journal=joma no-vol=13 cd-vols= no-issue= article-no= start-page=890048 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2022 dt-pub=20220812 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Anxiolytic-like effects of hochuekkito in lipopolysaccharide-treated mice involve interleukin-6 inhibition en-subtitle= kn-subtitle= en-abstract= kn-abstract=Hochuekkito (HET) is a Kampo medicine used to treat postoperative and post-illness general malaise and decreased motivation. HET is known to regulate immunity and modulate inflammation. However, the precise mechanism and effects of HET on inflammation-induced central nervous system disorders remain unclear. This study aimed to assess the effect of HET on inflammation-induced anxiety-like behavior and the mechanism underlying anxiety-like behavior induced by lipopolysaccharide (LPS). Institute of Cancer Research mice were treated with LPS (300 mu g/kg, intraperitoneally), a bacterial endotoxin, to induce systemic inflammation. The mice were administered HET (1.0 g/kg, orally) once a day for 2 weeks before LPS treatment. The light-dark box test and the hole-board test were performed 24 h after the LPS injection to evaluate the effects of HET on anxiety-like behaviors. Serum samples were obtained at 2, 5, and 24 h after LPS injection, and interleukin-6 (IL-6) levels in serum were measured. Human and mouse macrophage cells (THP-1 and RAW264.7 cells, respectively) were used to investigate the effect of HET on LPS-induced IL-6 secretion. The repeated administration of HET prevented anxiety-like behavior and decreased serum IL-6 levels in LPS-treated mice. HET significantly suppressed LPS-induced IL-6 secretion in RAW264.7 and THP-1 cells. Similarly, glycyrrhizin, one of the chemical constituents of HET, suppressed LPS-induced anxiety-like behaviors. Our study revealed that HET ameliorated LPS-induced anxiety-like behavior and inhibited IL-6 release in vivo and in vitro. Therefore, we postulate that HET may be useful against inflammation-induced anxiety-like behavior. en-copyright= kn-copyright= en-aut-name=UshioSoichiro en-aut-sei=Ushio en-aut-mei=Soichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=WadaYudai en-aut-sei=Wada en-aut-mei=Yudai kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=NakamuraMizuki en-aut-sei=Nakamura en-aut-mei=Mizuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MatsumotoDaiki en-aut-sei=Matsumoto en-aut-mei=Daiki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=HoshikaKota en-aut-sei=Hoshika en-aut-mei=Kota kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ShiromizuShoya en-aut-sei=Shiromizu en-aut-mei=Shoya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=IwataNaohiro en-aut-sei=Iwata en-aut-mei=Naohiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=KajizonoMakoto en-aut-sei=Kajizono en-aut-mei=Makoto kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=2 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=7 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=8 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=9 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=10 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=11 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= en-keyword=anxiolytic kn-keyword=anxiolytic en-keyword=inflammation kn-keyword=inflammation en-keyword=immunomodulation kn-keyword=immunomodulation en-keyword=macrophages kn-keyword=macrophages en-keyword=Kampo medicine kn-keyword=Kampo medicine END start-ver=1.4 cd-journal=joma no-vol=76 cd-vols= no-issue=2 article-no= start-page=167 end-page=172 dt-received= dt-revised= dt-accepted= dt-pub-year=2022 dt-pub=202204 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Retrospective Cohort Study of Clinical Efficacy and Safety of Cefozopran for Treating Febrile Neutropenia during Chemotherapy in Patients with Lung Cancer en-subtitle= kn-subtitle= en-abstract= kn-abstract=Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal. Since infection control is crucial in the management of FN, the antimicrobial agent cefozopran (CZOP) has been recommended but not approved for routine use in clinical care of FN in Japan. However, few studies of CZOP in the management of FN have used a thrice daily dose schedule. The aim of this study was to retrospectively compare the efficacy and safety of CZOP at a dose of 1 g three times daily to those of cefepime (CFPM) in the treatment of FN in our lung cancer patients. The response rates of the CZOP and CFPM groups were 89.5% (17/19 cases) and 83.0% (39/47 cases), respectively, with no significant difference between the two groups. The median duration of antimicrobial treatment was 6 days (4-10 days) in the CZOP group and 7 days (3-13 days) in the CFPM group, with no significant difference between groups. The incidence rates of adverse events were 21.1% (4/19 cases) in the CZOP group and 19.1% (9/47 cases) in the CFPM group. No adverse events of Grade 3 or higher were observed in either group. The findings of the present study suggest that CZOP administration at a dose of 1 g three times per day as an antimicrobial treatment alternative against FN. en-copyright= kn-copyright= en-aut-name=HigashionnaTsukasa en-aut-sei=Higashionna en-aut-mei=Tsukasa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=UshioSoichiro en-aut-sei=Ushio en-aut-mei=Soichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MurakawaKiminaka en-aut-sei=Murakawa en-aut-mei=Kiminaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=5 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=6 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= en-keyword=febrile neutropenia kn-keyword=febrile neutropenia en-keyword=cefozopran kn-keyword=cefozopran en-keyword=cefepime kn-keyword=cefepime en-keyword=lung cancer kn-keyword=lung cancer en-keyword=retrospective kn-keyword=retrospective END start-ver=1.4 cd-journal=joma no-vol=20 cd-vols= no-issue=3 article-no= start-page=598 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2019 dt-pub=20190130 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Region-Specific Neuroprotective Features of Astrocytes against Oxidative Stress Induced by 6-Hydroxydopamine en-subtitle= kn-subtitle= en-abstract= kn-abstract=In previous studies, we found regional differences in the induction of antioxidative molecules in astrocytes against oxidative stress, postulating that region-specific features of astrocytes lead region-specific vulnerability of neurons. We examined region-specific astrocytic features against dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA) as an oxidative stress using co-culture of mesencephalic neurons and mesencephalic or striatal astrocytes in the present study. The 6-OHDA-induced reduction of mesencephalic dopamine neurons was inhibited by co-culturing with astrocytes. The co-culture of midbrain neurons with striatal astrocytes was more resistant to 6-OHDA than that with mesencephalic astrocytes. Furthermore, glia conditioned medium from 6-OHDA-treated striatal astrocytes showed a greater protective effect on the 6-OHDA-induced neurotoxicity and oxidative stress than that from mesencephalic astrocytes. The cDNA microarray analysis showed that the number of altered genes in both mesencephalic and striatal astrocytes was fewer than that changed in either astrocyte. The 6-OHDA treatment, apparently up-regulated expressions of Nrf2 and some anti-oxidative or Nrf2-regulating phase II, III detoxifying molecules related to glutathione synthesis and export in the striatal astrocytes but not mesencephalic astrocytes. There is a profound regional difference of gene expression in astrocytes induced by 6-OHDA. These results suggest that protective features of astrocytes against oxidative stress are more prominent in striatal astrocytes, possibly by secreting humoral factors in striatal astrocytes. en-copyright= kn-copyright= en-aut-name=AsanumaMasato en-aut-sei=Asanuma en-aut-mei=Masato kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=Okumura-TorigoeNao en-aut-sei=Okumura-Torigoe en-aut-mei=Nao kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=MiyazakiIkuko en-aut-sei=Miyazaki en-aut-mei=Ikuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MurakamiShinki en-aut-sei=Murakami en-aut-mei=Shinki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medical, Dental and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medical, Dental and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medical, Dental and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medical, Dental and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medical, Dental and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medical, Dental and Pharmaceutical Sciences kn-affil= en-keyword=astrocyte kn-keyword=astrocyte en-keyword=neuroprotection kn-keyword=neuroprotection en-keyword=region-specificity kn-keyword=region-specificity en-keyword=striatum kn-keyword=striatum en-keyword=mesencephalon kn-keyword=mesencephalon en-keyword=oxidative stress kn-keyword=oxidative stress en-keyword=6-hydroxydopamine kn-keyword=6-hydroxydopamine en-keyword=Nrf2 kn-keyword=Nrf2 en-keyword=phase II detoxifying molecules kn-keyword=phase II detoxifying molecules END start-ver=1.4 cd-journal=joma no-vol=10 cd-vols= no-issue=1 article-no= start-page=20698 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2020 dt-pub=20201126 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection en-subtitle= kn-subtitle= en-abstract= kn-abstract=Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), is known to activate serotonin (5-HT) 1A receptor. Our recent study demonstrated that stimulation of astrocytic 5-HT1A receptors promoted astrocyte proliferation and upregulated antioxidative property in astrocytes to protect dopaminergic neurons against oxidative stress. Here, we evaluated the neuroprotective effects of mirtazapine against dopaminergic neurodegeneration in models of Parkinson's disease (PD). Mirtazapine administration attenuated the loss of dopaminergic neurons in the substantia nigra and increased the expression of the antioxidative molecule metallothionein (MT) in the striatal astrocytes of 6-hydroxydopamine (6-OHDA)-injected parkinsonian mice via 5-HT1A receptors. Mirtazapine protected dopaminergic neurons against 6-OHDA-induced neurotoxicity in mesencephalic neuron and striatal astrocyte cocultures, but not in enriched neuronal cultures. Mirtazapine-treated neuron-conditioned medium (Mir-NCM) induced astrocyte proliferation and upregulated MT expression via 5-HT1A receptors on astrocytes. Furthermore, treatment with medium from Mir-NCM-treated astrocytes protected dopaminergic neurons against 6-OHDA neurotoxicity, and these effects were attenuated by treatment with a MT-1/2-specific antibody or 5-HT1A antagonist. Our study suggests that mirtazapine could be an effective disease-modifying drug for PD and highlights that astrocytic 5-HT1A receptors may be a novel target for the treatment of PD. en-copyright= kn-copyright= en-aut-name=KikuokaRyo en-aut-sei=Kikuoka en-aut-mei=Ryo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=MiyazakiIkuko en-aut-sei=Miyazaki en-aut-mei=Ikuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KubotaNatsuki en-aut-sei=Kubota en-aut-mei=Natsuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MaedaMegumi en-aut-sei=Maeda en-aut-mei=Megumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KagawaDaiki en-aut-sei=Kagawa en-aut-mei=Daiki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=MoriyamaMasaaki en-aut-sei=Moriyama en-aut-mei=Masaaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=SatoAsuka en-aut-sei=Sato en-aut-mei=Asuka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=MurakamiShinki en-aut-sei=Murakami en-aut-mei=Shinki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=AsanumaMasato en-aut-sei=Asanuma en-aut-mei=Masato kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= affil-num=1 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=7 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=8 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=9 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=10 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=11 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= END start-ver=1.4 cd-journal=joma no-vol=74 cd-vols= no-issue=6 article-no= start-page=545 end-page=550 dt-received= dt-revised= dt-accepted= dt-pub-year=2020 dt-pub=202012 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance en-subtitle= kn-subtitle= en-abstract= kn-abstract=Polymorphisms in methotrexate transporter pathways have been associated with methotrexate toxicities and clearance. Recent genome-wide association studies have revealed that the SLCO1B1 T521C variant is associated with methotrexate elimination. We present a case of a pediatric patient with acute lymphoblastic leukemia who suffered from persistently high plasma methotrexate concentrations and acute kidney injuries after the admin-istration of a medium dose of methotrexate. Subsequent genetic analysis showed that he was a carrier of dys-functional genetic variants associated with methotrexate clearance. This case highlights that polymorphisms of methotrexate transporter pathways can adversely affect methotrexate elimination in a clinically significant manner. en-copyright= kn-copyright= en-aut-name=TatebeYasuhisa en-aut-sei=Tatebe en-aut-mei=Yasuhisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KanamitsuKiichiro en-aut-sei=Kanamitsu en-aut-mei=Kiichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KanzakiHirotaka en-aut-sei=Kanzaki en-aut-mei=Hirotaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=IshidaHisashi en-aut-sei=Ishida en-aut-mei=Hisashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=FujiwaraKaori en-aut-sei=Fujiwara en-aut-mei=Kaori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=WashioKana en-aut-sei=Washio en-aut-mei=Kana kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=ShimadaAkira en-aut-sei=Shimada en-aut-mei=Akira kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=TsukaharaHirokazu en-aut-sei=Tsukahara en-aut-mei=Hirokazu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=2 en-affil=Department of pediatrics, Okayama University Hospital kn-affil= affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=4 en-affil=Department of pediatrics, Okayama University Hospital kn-affil= affil-num=5 en-affil=Department of pediatrics, Okayama University Hospital kn-affil= affil-num=6 en-affil=Department of pediatrics, Okayama University Hospital kn-affil= affil-num=7 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=8 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=9 en-affil=Department of pediatrics, Okayama University Hospital kn-affil= affil-num=10 en-affil=Department of pediatrics, Okayama University Hospital kn-affil= en-keyword=methotrexate kn-keyword=methotrexate en-keyword=polymorphism kn-keyword=polymorphism en-keyword=drug elimination kn-keyword=drug elimination en-keyword=acute kidney injury kn-keyword=acute kidney injury en-keyword=acute lymphoblastic leukemia kn-keyword=acute lymphoblastic leukemia END start-ver=1.4 cd-journal=joma no-vol=74 cd-vols= no-issue=4 article-no= start-page=301 end-page=306 dt-received= dt-revised= dt-accepted= dt-pub-year=2020 dt-pub=202008 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Immobility-reducing Effects of Ketamine during the Forced Swim Test on 5-HT1A Receptor Activity in the Medial Prefrontal Cortex in an Intractable Depression Model en-subtitle= kn-subtitle= en-abstract= kn-abstract=Ketamine has been clinically proven to ameliorate depression, including treatment-resistant depression. The detailed mechanism of action of ketamine in treatment-resistant depression remains unclear. We examined the effects of ketamine on the immobility times of adrenocorticotropic hormone (ACTH)-treated rats during the forced swim test, and we explored the mechanism by which ketamine acts in this model. We investigated the neuroanatomical site of action by microinjecting ketamine into the medial prefrontal cortex of rats. A significant reduction of the rats’ immobility during the forced swim test was observed after the intraperitoneal injection of ketamine in both saline- and ACTH-treated rats. The microinjection of ketamine into the medial prefrontal cortex also decreased immobility during the forced swim test in both saline- and ACTH-treated rats. The immobility-decreasing effect of intraperitoneally injected ketamine was blocked by administering WAY100635, a 5-HT1A receptor antagonist, into the medial prefrontal cortex. These findings contribute to the evidence that ketamine can be useful against treatment-resistant depressive conditions. The immobility-reducing effects of ketamine might be mediated by 5-HT1A receptor activity in the medial prefrontal cortex. en-copyright= kn-copyright= en-aut-name=TakahashiKei en-aut-sei=Takahashi en-aut-mei=Kei kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=UshioSoichiro en-aut-sei=Ushio en-aut-mei=Soichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= affil-num=1 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= en-keyword=ketamine kn-keyword=ketamine en-keyword=adrenocorticotropic hormone kn-keyword=adrenocorticotropic hormone en-keyword=forced swim test kn-keyword=forced swim test en-keyword=medial prefrontal cortex kn-keyword=medial prefrontal cortex en-keyword=5-HT1A receptor kn-keyword=5-HT1A receptor END start-ver=1.4 cd-journal=joma no-vol=6 cd-vols= no-issue=1 article-no= start-page=16 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2020 dt-pub=20200707 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Development of an appropriate simple suspension method for valganciclovir medication en-subtitle= kn-subtitle= en-abstract= kn-abstract=Background
Valganciclovir (VGC) is essential for preventing cytomegalovirus infections after transplants in adult and pediatric patients. In pediatric patients, VGC tablets have to be pulverized so that they can be delivered via nasogastric tubes. The “simple suspension method” is usually used to suspend tablets in hot water in Japan. However, the optimal suspension conditions and metering methods for preparing VGC suspensions using the simple suspension method are unclear. The purpose of this study was to clarify these issues.
Methods
VGC tablets were suspended in water (initial water temperature: 25 °C or 55 °C) using the simple suspension method. The residual rate of VGC after it had been suspended in hot water was determined using HPLC. In addition, the suspended solution was passed through 6, 8, and 12 Fr. gavage tubes. The VGC concentrations of suspensions produced using different preparation methods were also determined using HPLC.
Results
Cracking the surfaces of VGC tablets and suspending them in water at an initial temperature of 55 °C was effective at dissolving the tablets. The VGC concentration of the suspension remained stable for at least 80 min. Furthermore, the VGC concentration remained stable for 48 h during cold dark storage. Cracking the surfaces of VGC tablets could be a more effective metering method than preparing powder from VGC tablets. In addition, little VGC remained in 6, 8, or 12 Fr. gavage tubes after VGC solution was passed through them.
Conclusion
The amount of VGC should be measured carefully when preparing VGC solutions using the simple suspension method. en-copyright= kn-copyright= en-aut-name=MasaokaYasuyuki en-aut-sei=Masaoka en-aut-mei=Yasuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KawasakiYoichi en-aut-sei=Kawasaki en-aut-mei=Yoichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KikuokaRyo en-aut-sei=Kikuoka en-aut-mei=Ryo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=OgawaAtsushi en-aut-sei=Ogawa en-aut-mei=Atsushi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=WadaYudai en-aut-sei=Wada en-aut-mei=Yudai kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=UshioSoichiro en-aut-sei=Ushio en-aut-mei=Soichiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=3 en-affil=Department of Clinical Pharmacy,Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=5 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=6 en-affil=Department of Clinical Pharmacy,Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences kn-affil= affil-num=7 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=8 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=9 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= en-keyword=Valganciclovir kn-keyword=Valganciclovir en-keyword=Simple suspension method kn-keyword=Simple suspension method en-keyword=Stability kn-keyword=Stability en-keyword=HPLC kn-keyword=HPLC en-keyword=Gavage tube kn-keyword=Gavage tube END start-ver=1.4 cd-journal=joma no-vol=132 cd-vols= no-issue=1 article-no= start-page=29 end-page=33 dt-received= dt-revised= dt-accepted= dt-pub-year=2020 dt-pub=20200401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (47. Combination with general anesthetics) kn-title=薬物相互作用（47―全身麻酔薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=IgawaYusuke en-aut-sei=Igawa en-aut-mei=Yusuke kn-aut-name=井川祐輔 kn-aut-sei=井川 kn-aut-mei=祐輔 aut-affil-num=1 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name=江角悟 kn-aut-sei=江角 kn-aut-mei=悟 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=111 cd-vols= no-issue=3 article-no= start-page=849 end-page=856 dt-received= dt-revised= dt-accepted= dt-pub-year=2019 dt-pub=20191219 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers en-subtitle= kn-subtitle= en-abstract= kn-abstract=Molecular-targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2-positive breast cancer. However, acquired resistance of various cancers to molecular-targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib-resistant cell lines from HER2-amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to overcome the resistance. Our results revealed that amplification of YES1, which is a member of the SRC family, was amplified in two neratinib-resistant breast cancer cell lines and one lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of YES1 by dasatinib restored the sensitivity of the YES1-amplified cell lines to neratinib in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in vivo. This combination also induced downregulation of signaling molecules such as HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role in the emergence of resistance to HER2-targeted drugs, and that dasatinib enables such acquired resistance to neratinib to be overcome. en-copyright= kn-copyright= en-aut-name=TakedaTatsuaki en-aut-sei=Takeda en-aut-mei=Tatsuaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=YamamotoHiromasa en-aut-sei=Yamamoto en-aut-mei=Hiromasa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=SuzawaKen en-aut-sei=Suzawa en-aut-mei=Ken kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TomidaShuta en-aut-sei=Tomida en-aut-mei=Shuta kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=MiyauchiShunsaku en-aut-sei=Miyauchi en-aut-mei=Shunsaku kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ArakiKota en-aut-sei=Araki en-aut-mei=Kota kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=NakataKentaro en-aut-sei=Nakata en-aut-mei=Kentaro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=MiuraAkihiro en-aut-sei=Miura en-aut-mei=Akihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=NambaKei en-aut-sei=Namba en-aut-mei=Kei kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=ShienKazuhiko en-aut-sei=Shien en-aut-mei=Kazuhiko kn-aut-name=\ kn-aut-sei= kn-aut-mei=\ aut-affil-num=10 ORCID= en-aut-name=SohJunichi en-aut-sei=Soh en-aut-mei=Junichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=ShienTadahiko en-aut-sei=Shien en-aut-mei=Tadahiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= en-aut-name=ToyookaShinichi en-aut-sei=Toyooka en-aut-mei=Shinichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=15 ORCID= affil-num=1 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine,Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital kn-affil= affil-num=5 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=7 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=8 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=9 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=10 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=11 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=12 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=13 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine,Dentistry and Pharmaceutical Sciences kn-affil= affil-num=14 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine,Dentistry and Pharmaceutical Sciences kn-affil= affil-num=15 en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery,Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= en-keyword=breast cancer kn-keyword=breast cancer en-keyword=drug resistance kn-keyword=drug resistance en-keyword=lung cancer kn-keyword=lung cancer en-keyword=neratinib kn-keyword=neratinib en-keyword=YES1 kn-keyword=YES1 END start-ver=1.4 cd-journal=joma no-vol=131 cd-vols= no-issue=3 article-no= start-page=161 end-page=164 dt-received= dt-revised= dt-accepted= dt-pub-year=2019 dt-pub=20191202 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction（46. Blending change and interaction of an injection drug） kn-title=薬物相互作用（46―注射薬の配合変化 : 注射薬の物理的・化学的な相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=MorishitaYosuke en-aut-sei=Morishita en-aut-mei=Yosuke kn-aut-name=森下陽介 kn-aut-sei=森下 kn-aut-mei=陽介 aut-affil-num=1 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name=江角悟 kn-aut-sei=江角 kn-aut-mei=悟 aut-affil-num=2 ORCID= en-aut-name=NishiharaShigeki en-aut-sei=Nishihara en-aut-mei=Shigeki kn-aut-name=西原茂樹 kn-aut-sei=西原 kn-aut-mei=茂樹 aut-affil-num=3 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=4 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=5 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=5 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=9 cd-vols= no-issue=12 article-no= start-page=e033462 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2019 dt-pub=20191211 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Fall-related mortality trends in older Japanese adults aged >= 65 years: a nationwide observational study en-subtitle= kn-subtitle= en-abstract= kn-abstract=OBJECTIVES:
Fall-related mortality among older adults is a major public health issue, especially for ageing societies. This study aimed to investigate current trends in fall-related mortality in Japan using nationwide population-based data covering 1997-2016.
DESIGN:
We analysed fall-related deaths among older persons aged ≥65 years using the data provided by the Japanese Ministry of Health, Labour and Welfare.
RESULTS:
The crude and age-standardised mortality rates were calculated per 100 000 persons by stratifying by age (65-74, 75-84 and ≥85 years) and sex. To identify trend changes, a joinpoint regression model was applied by estimating change points and annual percentage change (APC). The total number of fall-related deaths in Japan increased from 5872 in 1997 to 8030 in 2016, of which 78.8% involved persons aged ≥65 years. The younger population (65-74 years) showed continuous and faster-decreasing trends for both men and women. Average APC among men aged ≥75 years did not decrease. Among middle-aged and older women (75-84 and ≥85 years) decreasing trends were observed. Furthermore, the age-adjusted mortality rate of men was approximately twice that of women, and it showed a faster decrease for women.
CONCLUSIONS:
Although Japanese healthcare has shown improvement in preventing fall-related deaths over the last two decades, the crude mortality for those aged over 85 years remains high, indicating difficulty in reducing fall-related deaths in the super-aged population. Further investigations to uncover causal factors for falls in older populations are required. en-copyright= kn-copyright= en-aut-name=HagiyaHideharu en-aut-sei=Hagiya en-aut-mei=Hideharu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KoyamaToshihiro en-aut-sei=Koyama en-aut-mei=Toshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=ZamamiYoshito en-aut-sei=Zamami en-aut-mei=Yoshito kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TatebeYasuhisa en-aut-sei=Tatebe en-aut-mei=Yasuhisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=FunahashiTomoko en-aut-sei=Funahashi en-aut-mei=Tomoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ShinomiyaKazuaki en-aut-sei=Shinomiya en-aut-mei=Kazuaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=HinotsuShiro en-aut-sei=Hinotsu en-aut-mei=Shiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=RakugiHiromi en-aut-sei=Rakugi en-aut-mei=Hiromi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=KanoMitsunobu R. en-aut-sei=Kano en-aut-mei=Mitsunobu R. kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= affil-num=1 en-affil=Department of General Internal Medicine, Osaka University Hospital kn-affil= affil-num=2 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University kn-affil= affil-num=3 en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School kn-affil= affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=5 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University kn-affil= affil-num=6 en-affil=Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences Tokushima Bunri University kn-affil= affil-num=7 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=8 en-affil=Department of Biostatistics, Sapporo Medical University kn-affil= affil-num=9 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=10 en-affil=Department of General Internal Medicine, Osaka University Hospital kn-affil= affil-num=11 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University kn-affil= en-keyword=adult intensive & critical care kn-keyword=adult intensive & critical care en-keyword=epidemiology kn-keyword=epidemiology en-keyword=geriatric medicine kn-keyword=geriatric medicine en-keyword=health & safety kn-keyword=health & safety en-keyword=health policy kn-keyword=health policy en-keyword=public health kn-keyword=public health END start-ver=1.4 cd-journal=joma no-vol=9 cd-vols= no-issue= article-no= start-page=20235 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2019 dt-pub=20191227 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Place of death trends among patients with dementia in Japan: a population-based observational study en-subtitle= kn-subtitle= en-abstract= kn-abstract=Dementia is a major public health concern in ageing societies. Although the population of Japan is among the most aged worldwide, long-term trends in the place of death (PoD) among patients with dementia is unknown. In this Japanese nationwide observational study, we analysed trends in PoD using the data of patients with dementia who were aged >= 65 years and died during 1999-2016. Trends in the crude death rates and PoD frequencies were analysed using the Joinpoint regression model. Changes in these trends were assessed using the Joinpoint regression analysis in which significant change points, the annual percentage change (APC) and average APCs (AAPC) in hospitals, homes, or nursing homes were estimated. During 1999-2016, the number of deaths among patients with dementia increased from 3,235 to 23,757 (total: 182,000). A trend analysis revealed increased mortality rates, with an AAPC of 8.2% among men and 9.3% among women. Most patients with dementia died in the hospital, although the prevalence of hospital deaths decreased (AAPC: -1.0%). Moreover, the prevalence of nursing home deaths increased (AAPC: 5.6%), whereas the prevalence of home deaths decreased (AAPC: -5.8%). These findings support a reconsideration of the end-of-life care provided to patients with dementia. en-copyright= kn-copyright= en-aut-name=KoyamaToshihiro en-aut-sei=Koyama en-aut-mei=Toshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=SasakiMisato en-aut-sei=Sasaki en-aut-mei=Misato kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=HagiyaHideharu en-aut-sei=Hagiya en-aut-mei=Hideharu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ZamamiYoshito en-aut-sei=Zamami en-aut-mei=Yoshito kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=FunahashiTomoko en-aut-sei=Funahashi en-aut-mei=Tomoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=OhshimaAyako en-aut-sei=Ohshima en-aut-mei=Ayako kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=TatebeYasuhisa en-aut-sei=Tatebe en-aut-mei=Yasuhisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=MikamiNaoko en-aut-sei=Mikami en-aut-mei=Naoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=ShinomiyaKazuaki en-aut-sei=Shinomiya en-aut-mei=Kazuaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=HinotsuShiro en-aut-sei=Hinotsu en-aut-mei=Shiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=KanoMitsunobu R. en-aut-sei=Kano en-aut-mei=Mitsunobu R. kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= affil-num=1 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University kn-affil= affil-num=2 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University kn-affil= affil-num=3 en-affil=Department of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University kn-affil= affil-num=4 en-affil=Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School kn-affil= affil-num=5 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University kn-affil= affil-num=6 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University kn-affil= affil-num=7 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=8 en-affil=Division of Pharmacy, Chiba University Hospital kn-affil= affil-num=9 en-affil=Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University kn-affil= affil-num=10 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=11 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil= affil-num=12 en-affil=Department of Biostatistics, Sapporo Medical University kn-affil= affil-num=13 en-affil=Department of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University kn-affil= END start-ver=1.4 cd-journal=joma no-vol=132 cd-vols= no-issue= article-no= start-page=104608 end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2020 dt-pub=20200131 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes en-subtitle= kn-subtitle= en-abstract= kn-abstract=Astrocytes exert neuroprotective effects through production of antioxidant molecules and neurotrophic factors. A recent study showed that stimulation of astrocyte serotonin 1A (5-HT1A) receptors promotes astrocyte proliferation and upregulation of the antioxidant molecules metallothionein (MT)-1,2, which protect dopaminergic neurons against oxidative stress. Rotigotine, an anti-parkinsonian drug, can bind to dopamine and 5-HT1A receptors. In this study, we examined neuroprotective effects of rotigotine in models of Parkinson's disease and involvement of astrocyte 5-HT1A receptors in neuroprotective effects of rotigotine against dopaminergic neurodegeneration. Rotigotine increased the number of astrocytes and MT-1,2 expression in cultured astrocytes. Pretreatment with conditioned media from rotigotine-treated astrocytes significantly inhibited 6-hydroxydopamine (6-OHDA)-induced dopaminergic neurotoxicity. These effects were completely blocked by a 5-HT1A antagonist or MT-1,2 specific antibody. Subcutaneous administration of rotigotine increased MT-1,2 expression in striatal astrocytes and prevented reduction of dopaminergic neurons in the substantia nigra of a 6-OHDA-lesioned mouse model of Parkinson's disease. These effects were blocked by co-administration with a 5-HT1A antagonist. These results suggest that rotigotine exerts neuroprotective effects through upregulation of MT expression in astrocytes by targeting 5-HT1A receptors. Our findings provide a possible therapeutic application of rotigotine to prevent dopaminergic neurodegeneration in Parkinson's disease. en-copyright= kn-copyright= en-aut-name=IsookaNami en-aut-sei=Isooka en-aut-mei=Nami kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=MiyazakiIkuko en-aut-sei=Miyazaki en-aut-mei=Ikuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KikuokaRyo en-aut-sei=Kikuoka en-aut-mei=Ryo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=WadaKouichi en-aut-sei=Wada en-aut-mei=Kouichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=NakayamaErika en-aut-sei=Nakayama en-aut-mei=Erika kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=ShinKotaro en-aut-sei=Shin en-aut-mei=Kotaro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=YamamotoDaichi en-aut-sei=Yamamoto en-aut-mei=Daichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=AsanumaMasato en-aut-sei=Asanuma en-aut-mei=Masato kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= affil-num=1 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=3 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=4 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=7 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=8 en-affil=Department of Clinical Pharmacy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=9 en-affil=Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= en-keyword=Astrocyte kn-keyword=Astrocyte en-keyword=Dopamine agonist kn-keyword=Dopamine agonist en-keyword=Metallothionein kn-keyword=Metallothionein en-keyword=Parkinson's disease kn-keyword=Parkinson's disease en-keyword=Rotigotine kn-keyword=Rotigotine en-keyword=Serotonin 1A receptor kn-keyword=Serotonin 1A receptor END start-ver=1.4 cd-journal=joma no-vol=129 cd-vols= no-issue=2 article-no= start-page=131 end-page=136 dt-received= dt-revised= dt-accepted= dt-pub-year=2017 dt-pub=20170801 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (39. Drug interaction in prostate cancer therapy) kn-title=薬物相互作用 (39―前立腺がん治療薬と薬物相互作用) en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=KanzakiHirotaka en-aut-sei=Kanzaki en-aut-mei=Hirotaka kn-aut-name=神崎浩孝 kn-aut-sei=神崎 kn-aut-mei=浩孝 aut-affil-num=1 ORCID= en-aut-name=TanakaYuta en-aut-sei=Tanaka en-aut-mei=Yuta kn-aut-name=田中雄太 kn-aut-sei=田中 kn-aut-mei=雄太 aut-affil-num=2 ORCID= en-aut-name=MaruoAkinori en-aut-sei=Maruo en-aut-mei=Akinori kn-aut-name=丸尾陽成 kn-aut-sei=丸尾 kn-aut-mei=陽成 aut-affil-num=3 ORCID= en-aut-name=NishiharaShigeki en-aut-sei=Nishihara en-aut-mei=Shigeki kn-aut-name=西原茂樹 kn-aut-sei=西原 kn-aut-mei=茂樹 aut-affil-num=4 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=5 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=6 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=5 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=6 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=37 cd-vols= no-issue=6 article-no= start-page=1258 end-page=1266 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=201512 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Exploring autistic-like traits relating to empathic attitude and psychological distress in hospital pharmacists en-subtitle= kn-subtitle= en-abstract= kn-abstract=BACKGROUND: Pharmacists are expected to play a key role in modern cancer care. Research suggests that an empathic approach and attitude in medical staff improves the quality of patient care. An empathic attitude and psychological distress are thought to be associated with autistic-like traits, but little is known about such traits. OBJECTIVE: In this study, we aimed to clarify the associations among autistic-like traits, empathic attitude in a medical context, and psychological health in hospital pharmacists. SETTING: Eligibility criteria for inclusion were certified pharmacists working at hospitals for patient care who returned their questionnaires. METHOD: Eight hundred and twenty-three hospital pharmacists completed a number of self-administered questionnaires anonymously by mail. MAIN OUTCOME MEASURES: Scores were obtained on the Autism-Spectrum Quotient, the Jefferson Scale of Empathy, the General Health Questionnaire-12, and subscales of the Interpersonal Reactivity Index (Perspective Taking, IRI-Empathic Concern, IRIPersonal Distress). We performed correlation and mediation analyses to confirm that the empathy and general health questionnaires were associated with autism-spectrum quotient scores, and with each IRI subscale. RESULTS: Complete responses were obtained from 379 pharmacists comprising 151 males (39.8 %) with a mean age of 37.7 ± 10.8 years (missing data, n = 13) and a median of 11 years after qualification as a pharmacist. Autism-Spectrum Quotient scores were inversely correlated with empathy (r = -0.22, p < 0.001) and positively correlated with general health scores (r = 0.40, p < 0.001). In the models with mediation, the inverse correlation between autism-spectrum quotient and empathy scores was mediated indirectly by IRI-Perspective Taking and IRI-Empathic Concern, and the positive correlation between autism-spectrum quotient and general health was mediated indirectly by IRI-Personal Distress. There were also direct effects, with significant effects of autism-spectrum quotient on empathy and general health scores. CONCLUSION: Our findings suggest that autistic-like traits affect both empathic attitude in a medical context and the psychological health of pharmacists. We recommend that to improve empathy in those with high levels of autistic-like traits, we may need to develop specialized interventions, such as improving communication skills training. en-copyright= kn-copyright= en-aut-name=HiguchiYuji en-aut-sei=Higuchi en-aut-mei=Yuji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=UchitomiYosuke en-aut-sei=Uchitomi en-aut-mei=Yosuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=FujimoriMaiko en-aut-sei=Fujimori en-aut-mei=Maiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KoyamaToshihiro en-aut-sei=Koyama en-aut-mei=Toshihiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KataokaHitomi en-aut-sei=Kataoka en-aut-mei=Hitomi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=InagakiMasatoshi en-aut-sei=Inagaki en-aut-mei=Masatoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= affil-num=1 en-affil=Department of NeuropsychiatryOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=2 en-affil=Innovation Center for Supportive, Palliative and Psychosocial CareNational Cancer Center kn-affil= affil-num=3 en-affil=Center for Suicide Prevention, National Institute of Mental HealthNational Center for Neurology and Psychiatry kn-affil= affil-num=4 en-affil=Department of Clinical PharmacyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=5 en-affil=Department of Primary Care and Medical EducationOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=6 en-affil=Department of Clinical PharmacyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=7 en-affil=Department of Clinical PharmacyOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences kn-affil= affil-num=8 en-affil=Department of NeuropsychiatryOkayama University Hospital kn-affil= en-keyword=Empathy kn-keyword=Empathy en-keyword= Hospital pharmacist kn-keyword= Hospital pharmacist en-keyword= Japan kn-keyword= Japan en-keyword= Pharmaceutical care kn-keyword= Pharmaceutical care END start-ver=1.4 cd-journal=joma no-vol=129 cd-vols= no-issue=1 article-no= start-page=53 end-page=57 dt-received= dt-revised= dt-accepted= dt-pub-year=2017 dt-pub=20170403 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (38. Combination with novel hypnotic drugs : ramelteon and suvorexant) kn-title=薬物相互作用 （ 38 - 新規睡眠薬 : ラメルテオン, スボレキサントの相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=KuboKazuko en-aut-sei=Kubo en-aut-mei=Kazuko kn-aut-name=久保和子 kn-aut-sei=久保 kn-aut-mei=和子 aut-affil-num=1 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name=江角悟 kn-aut-sei=江角 kn-aut-mei=悟 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=128 cd-vols= no-issue=3 article-no= start-page=231 end-page=235 dt-received= dt-revised= dt-accepted= dt-pub-year=2016 dt-pub=20161201 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (37. Combination with novel direct-acting antivirals for hepatitis C) kn-title=薬物相互作用（37―新規Ｃ型肝炎治療薬の相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=MiyamotoMasashi en-aut-sei=Miyamoto en-aut-mei=Masashi kn-aut-name=宮本理史 kn-aut-sei=宮本 kn-aut-mei=理史 aut-affil-num=1 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name=江角悟 kn-aut-sei=江角 kn-aut-mei=悟 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=128 cd-vols= no-issue=2 article-no= start-page=141 end-page=146 dt-received= dt-revised= dt-accepted= dt-pub-year=2016 dt-pub=20160801 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (36. Combination with oral molecular target drugs in lung cancer) kn-title=薬物相互作用（36―肺癌領域における経口分子標的治療薬） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=HigashionnaTsukasa en-aut-sei=Higashionna en-aut-mei=Tsukasa kn-aut-name=東恩納司 kn-aut-sei=東恩納 kn-aut-mei=司 aut-affil-num=1 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name=江角悟 kn-aut-sei=江角 kn-aut-mei=悟 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil=Department of Pharmacy, Okayama University Hospital kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=128 cd-vols= no-issue=1 article-no= start-page=53 end-page=59 dt-received= dt-revised= dt-accepted= dt-pub-year=2016 dt-pub=20160401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (35. Opioid-analgesic drug interactions) kn-title=薬物相互作用 (35―オピオイド鎮痛薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=SadaHikaru en-aut-sei=Sada en-aut-mei=Hikaru kn-aut-name=佐田光 kn-aut-sei=佐田 kn-aut-mei=光 aut-affil-num=1 ORCID= en-aut-name=KajizonoMakoto en-aut-sei=Kajizono en-aut-mei=Makoto kn-aut-name=鍛治園誠 kn-aut-sei=鍛治園 kn-aut-mei=誠 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=127 cd-vols= no-issue=3 article-no= start-page=245 end-page=249 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=20151201 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (34. Drug interactions of food and medicine) kn-title=薬物相互作用 (34―食事と薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=HinoHayato en-aut-sei=Hino en-aut-mei=Hayato kn-aut-name=日野隼人 kn-aut-sei=日野 kn-aut-mei=隼人 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院 affil-num=2 en-affil= kn-affil=岡山大学病院 affil-num=3 en-affil= kn-affil=岡山大学病院 END start-ver=1.4 cd-journal=joma no-vol=127 cd-vols= no-issue=2 article-no= start-page=151 end-page=154 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=20150803 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (33. Combination with antimicrobial agents) kn-title=薬物相互作用（33―抗菌薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=TasakaKen en-aut-sei=Tasaka en-aut-mei=Ken kn-aut-name=田坂健 kn-aut-sei=田坂 kn-aut-mei=健 aut-affil-num=1 ORCID= en-aut-name=ShiraishiNaoko en-aut-sei=Shiraishi en-aut-mei=Naoko kn-aut-name=白石奈緒子 kn-aut-sei=白石 kn-aut-mei=奈緒子 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院 affil-num=2 en-affil= kn-affil=岡山大学病院 affil-num=3 en-affil= kn-affil=岡山大学病院 affil-num=4 en-affil= kn-affil=岡山大学病院 END start-ver=1.4 cd-journal=joma no-vol=29 cd-vols= no-issue=4 article-no= start-page=1027 end-page=1033 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=2014 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Utility of simple suspension method compared to loss of drug using crushing method on tube administration kn-title=粉砕法による経管投与における薬剤量損失に対する簡易懸濁法の有用性についての検討 en-subtitle= kn-subtitle= en-abstract=Objective: In the past, a conventional crushing method was used for the administration of tablets or capsules by tube in patients with dysphagia. However, this method has several problems, such as a loss of the drug amount and tube clogging. Recently, tube administration by a simple suspension method was developed to solve these problems in the conventional crushing method. Methods: In the present study, we investigated to what extent the dosage amount is lost using the simple suspension method compared to crushing method, employing 5 drugs which are frequently administered by tube in Okayama University Hospital. Results: Drug weights of the 5 agents decreased by 70 ～ 90% in the grinding and packaging processes because of drug adhesion to the mortar, packaging machine, and drug package paper. The suspension of all drugs using the simple suspension method was uniform, while only the suspension of Warfarin® ground using the crushing method was shown to be showed inhomogeneous, which is expected to lead to a loss of drug. The drug content on assuming clinical a setting after tube passage was compared between the two methods. The recovery of warfarin®, characterized as unstable using the crushing method, was nearly 50%, but loss was prevented by 80% with the use of bags of medicine. For the simple suspension method, the recovery of warfarin® was almost 100%. Conclusion: The results of this study suggest that the simple suspension method is particularly effective for the tube administration of drugs characterized as unstable. kn-abstract=【目的】従来の薬剤経管投与法である粉砕法は薬効の減少につながる薬剤量の損失が指摘されている。そこで粉砕法による薬剤量損失に対する簡易懸濁法の有用性について検討した。 【方法】頻繁に粉砕指示がなされる5種類の薬剤を用いて粉砕・分包による薬物含量減少、薬剤調製時の懸濁性および実際の経管投与を想定した薬物含量について2つの方法を比較した。 【結果】薬剤を粉砕・分包するとそれぞれの薬物含量は減少した。またワーファリン®錠を粉砕して水に溶解すると完全には懸濁せず、小さな塊が生じたが、簡易懸濁法では均一に懸濁した。ワーファリン®錠の経管投与を想定した実験において粉砕法では薬物含量が大幅に減少したが、簡易懸濁法では、ほとんど損失が認められなかった。【結論】簡易懸濁法は粉砕法に比べて薬剤損失の面で有用性が高いことが示唆され、ワーファリン®錠のように安定性が悪い薬剤では特に適正な薬物投与に貢献出来ると考えられる。 en-copyright= kn-copyright= en-aut-name=ZamamiYoshito en-aut-sei=Zamami en-aut-mei=Yoshito kn-aut-name=座間味義人 kn-aut-sei=座間味 kn-aut-mei=義人 aut-affil-num=1 ORCID= en-aut-name=KoyamaToshihiro en-aut-sei=Koyama en-aut-mei=Toshihiro kn-aut-name=小山敏広 kn-aut-sei=小山 kn-aut-mei=敏広 aut-affil-num=2 ORCID= en-aut-name=AibaTetsuya en-aut-sei=Aiba en-aut-mei=Tetsuya kn-aut-name=合葉哲也 kn-aut-sei=合葉 kn-aut-mei=哲也 aut-affil-num=3 ORCID= en-aut-name=AmanoManabu en-aut-sei=Amano en-aut-mei=Manabu kn-aut-name=天野学 kn-aut-sei=天野 kn-aut-mei=学 aut-affil-num=4 ORCID= en-aut-name=AndoTetsuaki en-aut-sei=Ando en-aut-mei=Tetsuaki kn-aut-name=安藤哲信 kn-aut-sei=安藤 kn-aut-mei=哲信 aut-affil-num=5 ORCID= en-aut-name=KurataNaomi en-aut-sei=Kurata en-aut-mei=Naomi kn-aut-name=倉田なおみ kn-aut-sei=倉田 kn-aut-mei=なおみ aut-affil-num=6 ORCID= en-aut-name=NawaHideki en-aut-sei=Nawa en-aut-mei=Hideki kn-aut-name=名和秀起 kn-aut-sei=名和 kn-aut-mei=秀起 aut-affil-num=7 ORCID= en-aut-name=NakuraHironori en-aut-sei=Nakura en-aut-mei=Hironori kn-aut-name=名倉弘哲 kn-aut-sei=名倉 kn-aut-mei=弘哲 aut-affil-num=8 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=9 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=岡山大学大学院 医歯薬学総合研究科 affil-num=2 en-affil= kn-affil=岡山大学大学院 医歯薬学総合研究科 affil-num=3 en-affil= kn-affil=岡山大学大学院 医歯薬学総合研究科 affil-num=4 en-affil= kn-affil=兵庫医療大学 薬学部 affil-num=5 en-affil= kn-affil=吉備高原ルミエール病院 薬剤科 affil-num=6 en-affil= kn-affil=昭和大学 薬学部 affil-num=7 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=8 en-affil= kn-affil=岡山大学大学院 医歯薬学総合研究科 affil-num=9 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=10 en-affil= kn-affil=岡山大学病院 薬剤部 en-keyword=簡易懸濁法 (simple suspension method) kn-keyword=簡易懸濁法 (simple suspension method) en-keyword=経管投与 (tube administration) kn-keyword=経管投与 (tube administration) en-keyword=薬剤量の損失 (loss of drug amount) kn-keyword=薬剤量の損失 (loss of drug amount) END start-ver=1.4 cd-journal=joma no-vol=127 cd-vols= no-issue=1 article-no= start-page=59 end-page=61 dt-received= dt-revised= dt-accepted= dt-pub-year=2015 dt-pub=20150401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (32. Drug interaction in novel oral anticoagulants) kn-title=薬物相互作用 (32―新規経口抗凝固薬における薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=IdaHiromi en-aut-sei=Ida en-aut-mei=Hiromi kn-aut-name=猪田宏美 kn-aut-sei=猪田 kn-aut-mei=宏美 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=126 cd-vols= no-issue=3 article-no= start-page=245 end-page=248 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=20141201 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (31. drug interaction in hormonal breast cancer therapy) kn-title=薬物相互作用 (31―乳がんホルモン療法における薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=MasaokaYasuyuki en-aut-sei=Masaoka en-aut-mei=Yasuyuki kn-aut-name=正岡康幸 kn-aut-sei=正岡 kn-aut-mei=康幸 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=68 cd-vols= no-issue=5 article-no= start-page=255 end-page=262 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=201410 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Characteristics of the Runway Model of Intracranial Self-stimulation Behavior and Comparison with Other Motivated Behaviors en-subtitle= kn-subtitle= en-abstract= kn-abstract=Motivation incorporates several psychological aspects that produce reward-related and learning behaviors. Although reward-related behavior is reported to be mediated by the dopaminergic reward pathway, the involvement of dopaminergic systems in motivated behavior has not been fully clarified. Several experimental methodologies for motivational behavior have been reported, but pharmacological characteristics seem to vary among these methodologies. In this review, we attempt to summarize three main concepts:(1) the relationship of dopamine neuron physiology with motivated behavior, (2) the pharmacological characteristics of the runway intracranial self-stimulation model, and (3) the behavioral distinction of disparate motivated behaviors. en-copyright= kn-copyright= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KawasakiYoichi en-aut-sei=Kawasaki en-aut-mei=Yoichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=2 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=3 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=4 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=5 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital en-keyword=motivation kn-keyword=motivation en-keyword=reward kn-keyword=reward en-keyword=dopamine kn-keyword=dopamine en-keyword=operant behavior kn-keyword=operant behavior en-keyword=intracranial self-stimulation kn-keyword=intracranial self-stimulation END start-ver=1.4 cd-journal=joma no-vol=126 cd-vols= no-issue=2 article-no= start-page=159 end-page=163 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=20140801 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (30. combination with therapeutic drugs for chronic pain) kn-title=薬物相互作用 (30―慢性疼痛治療薬の相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=OgawaAtsushi en-aut-sei=Ogawa en-aut-mei=Atsushi kn-aut-name=小川敦 kn-aut-sei=小川 kn-aut-mei=敦 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=126 cd-vols= no-issue=1 article-no= start-page=59 end-page=63 dt-received= dt-revised= dt-accepted= dt-pub-year=2014 dt-pub=20140401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (29. drug interaction of steroids) kn-title=薬物相互作用(29―ステロイドの薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=HayashiYouko en-aut-sei=Hayashi en-aut-mei=Youko kn-aut-name=林瑶子 kn-aut-sei=林 kn-aut-mei=瑶子 aut-affil-num=1 ORCID= en-aut-name=NawaHideki en-aut-sei=Nawa en-aut-mei=Hideki kn-aut-name=名和秀起 kn-aut-sei=名和 kn-aut-mei=秀起 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=125 cd-vols= no-issue=3 article-no= start-page=259 end-page=262 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=20131202 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (28. combination with therapeutic drugs used to treat overactive bladder) kn-title=薬物相互作用 (28―過活動膀胱治療薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=HarutaYusuke en-aut-sei=Haruta en-aut-mei=Yusuke kn-aut-name=晴田佑介 kn-aut-sei=晴田 kn-aut-mei=佑介 aut-affil-num=1 ORCID= en-aut-name=KawasakiYoichi en-aut-sei=Kawasaki en-aut-mei=Yoichi kn-aut-name=河崎陽一 kn-aut-sei=河崎 kn-aut-mei=陽一 aut-affil-num=2 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=4 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=67 cd-vols= no-issue=5 article-no= start-page=319 end-page=324 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=201310 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Preparation of Enteric-coated Capsules of Beclomethasone Dipropionate for Patients with Intestinal Graft-versus-Host Disease and a Case Study en-subtitle= kn-subtitle= en-abstract= kn-abstract=Graft-versus-host disease (GVHD) is a major concern in transplantation patients. Gut GVHD is accompanied by diarrhea, abdominal pain, and/or melena. Although oral treatment with corticosteroids (CSs) is effective in treating gut GVHD, it can cause adverse reactions that affect the entire body. Topical administration of CSs can be effective in treating diseases in which lesions are limited locally, because adverse reactions can then be alleviated. In this study, we examine and discuss an enteric-coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University Hospital. The BDP-EC did not dissolve in solution 1 (pH1.2), and began disintegrating in solution 2 (pH6.8) after 5min, with a mean dissolution rate at 15min of 85%. We then used the capsule to treat a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation. Clinically, the frequency of diarrhea decreased after BDP-EC administration. In addition, we were able to decrease the prednisolone equivalent dose. Symptoms associated with adverse reactions to BDP were not observed during the hospitalization period. These findings suggest that the administration of BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs. en-copyright= kn-copyright= en-aut-name=MurakawaKiminaka en-aut-sei=Murakawa en-aut-mei=Kiminaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=SatoTomoaki en-aut-sei=Sato en-aut-mei=Tomoaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=MaedaYoshinobu en-aut-sei=Maeda en-aut-mei=Yoshinobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=TanimotoMitsune en-aut-sei=Tanimoto en-aut-mei=Mitsune kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=2 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=3 en-affil= kn-affil=Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=4 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=5 en-affil= kn-affil=Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=6 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital en-keyword=beclomethasone kn-keyword=beclomethasone en-keyword=intestinal graft-versus-host disease kn-keyword=intestinal graft-versus-host disease en-keyword=enteric-coated capsule kn-keyword=enteric-coated capsule en-keyword=in-hospital formulation kn-keyword=in-hospital formulation END start-ver=1.4 cd-journal=joma no-vol=125 cd-vols= no-issue=2 article-no= start-page=163 end-page=167 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=20130801 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (27. anti-emetics during anti-cancer chemotherapy) kn-title=薬物相互作用（27―がん化学療法における制吐剤の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=KurataYasuko en-aut-sei=Kurata en-aut-mei=Yasuko kn-aut-name=蔵田靖子 kn-aut-sei=蔵田 kn-aut-mei=靖子 aut-affil-num=1 ORCID= en-aut-name=FujiwaraSatoko en-aut-sei=Fujiwara en-aut-mei=Satoko kn-aut-name=藤原聡子 kn-aut-sei=藤原 kn-aut-mei=聡子 aut-affil-num=2 ORCID= en-aut-name=KajizonoMakoto en-aut-sei=Kajizono en-aut-mei=Makoto kn-aut-name=鍛治園誠 kn-aut-sei=鍛治園 kn-aut-mei=誠 aut-affil-num=3 ORCID= en-aut-name=AoyagiMegumu en-aut-sei=Aoyagi en-aut-mei=Megumu kn-aut-name=青柳恵 kn-aut-sei=青柳 kn-aut-mei=恵 aut-affil-num=4 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=5 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=4 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=5 en-affil= kn-affil=岡山大学病院 薬剤部 affil-num=6 en-affil= kn-affil=岡山大学病院 薬剤部 END start-ver=1.4 cd-journal=joma no-vol=125 cd-vols= no-issue=1 article-no= start-page=73 end-page=75 dt-received= dt-revised= dt-accepted= dt-pub-year=2013 dt-pub=20130401 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction(26. combination with therapeutic drugs used to treat hyperuricemia) kn-title=薬物相互作用(26―高尿酸血症治療薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=MakitaTakashi en-aut-sei=Makita en-aut-mei=Takashi kn-aut-name=槇田崇志 kn-aut-sei=槇田 kn-aut-mei=崇志 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=3 ORCID= affil-num=1 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学病院　薬剤部 affil-num=3 en-affil= kn-affil=岡山大学病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=64 cd-vols= no-issue=4 article-no= start-page=219 end-page=223 dt-received= dt-revised= dt-accepted= dt-pub-year=2010 dt-pub=201008 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Effects of Imipramine and Lithium on the Suppression of Cell Proliferation in the Dentate Gyrus of the Hippocampus in Adrenocorticotropic Hormone-treated Rats en-subtitle= kn-subtitle= en-abstract= kn-abstract=We examined the influence of chronic adrenocorticotropic hormone (ACTH) treatment on the number of Ki-67-positive cells in the dentate gyrus of the hippocampus in rats. ACTH treatment for 14 days decreased the number of such cells. The administration of imipramine or lithium alone for 14 days had no effect in saline-treated rats. The effect of ACTH was blocked by the administration of imipramine. Furthermore, the coadministration of imipramine and lithium for 14 days significantly increased the number of Ki-67-positive cells in both the saline and ACTH-treated rats. The coadministration of imipramine and lithium normalized the cell proliferation in the dentate gyrus of the hippocampus in rats treated with ACTH. en-copyright= kn-copyright= en-aut-name=DoiMaho en-aut-sei=Doi en-aut-mei=Maho kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=MiyazakiIkuko en-aut-sei=Miyazaki en-aut-mei=Ikuko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=NagamachiTomoko en-aut-sei=Nagamachi en-aut-mei=Tomoko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ShinomiyaKazuaki en-aut-sei=Shinomiya en-aut-mei=Kazuaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=MatsunagaHisashi en-aut-sei=Matsunaga en-aut-mei=Hisashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KawasakiHiromu en-aut-sei=Kawasaki en-aut-mei=Hiromu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=AsanumaMasato en-aut-sei=Asanuma en-aut-mei=Masato kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= affil-num=1 en-affil= kn-affil=Department of Pharmaceutical Care and Health Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=2 en-affil= kn-affil=Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=3 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=4 en-affil= kn-affil=Department of Pharmaceutical Care and Health Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=5 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=6 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=7 en-affil= kn-affil=Department of Clinical Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=8 en-affil= kn-affil=Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=9 en-affil= kn-affil=Shujitsu University School of Pharmacy affil-num=10 en-affil= kn-affil=Department of Pharmaceutical Care and Health Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences en-keyword=ACTH kn-keyword=ACTH en-keyword=imipramine kn-keyword=imipramine en-keyword=lithium kn-keyword=lithium en-keyword=proliferation kn-keyword=proliferation en-keyword=Ki-67 kn-keyword=Ki-67 END start-ver=1.4 cd-journal=joma no-vol=89 cd-vols= no-issue=3 article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2008 dt-pub=20080520 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment–resistant depression: Involvement of 5-HT 2A receptors? en-subtitle= kn-subtitle= en-abstract= kn-abstract=

The use of carbamazepine has been reported to be an effective treatment for severe depression. We have already shown that the antidepressant-like effects of tricyclic antidepressants in the rat forced swim test (FST) are blocked by chronic treatment with adrenocorticotropic hormone (ACTH). In the present study, we examined the effect of the chronic administration of carbamazepine on the FST and the wet-dog shakes induced by (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aiminopropane (DOI), a 5-HT2A receptor agonist, in ACTH-treated rats. Chronic administration of carbamazepine did not affect the duration of immobility in saline-treated and ACTH-treated rats. The reduction of immobility, induced by chronic administration of imipramine, was blocked by treatment with ACTH. When carbamazepine was administered concurrently with imipramine, we observed a significant decrease in immobility in rats treated with ACTH. Chronic ACTH treatment increased the number of the wet-dog shakes induced by DOI. This effect of ACTH was significantly increased by the coadministration of carbamazepine and imipramine. These results suggest that the use of carbamazepine together with tricyclic antidepressants had the effect of reducing immobility time in the FST in a tricyclic antidepressant-treatment-resistant depressive model induced by chronic ACTH treatment.

en-copyright= kn-copyright= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=AkiyamaKozue en-aut-sei=Akiyama en-aut-mei=Kozue kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KitagawaKouhei en-aut-sei=Kitagawa en-aut-mei=Kouhei kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=ShibataKazuhiko en-aut-sei=Shibata en-aut-mei=Kazuhiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KawasakiHiromu en-aut-sei=Kawasaki en-aut-mei=Hiromu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SuemaruKatsuya en-aut-sei=Suemaru en-aut-mei=Katsuya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=ArakiHiroaki en-aut-sei=Araki en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Okayama University Medical School affil-num=3 en-affil= kn-affil=Okayama University Medical School affil-num=4 en-affil= kn-affil=Okayama University Medical School affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Ehime University Medical School affil-num=7 en-affil= kn-affil=Ehime University Medical School affil-num=8 en-affil= kn-affil=Okayama University Medical School affil-num=9 en-affil= kn-affil=Okayama University Medical School en-keyword=Imipramine kn-keyword=Imipramine en-keyword=Carbamazepine kn-keyword=Carbamazepine en-keyword=ACTH kn-keyword=ACTH en-keyword=5-HT2A receptor kn-keyword=5-HT2A receptor en-keyword=Forced swim test kn-keyword=Forced swim test en-keyword=Wet-dog shakes kn-keyword=Wet-dog shakes en-keyword=Treatment–resistant kn-keyword=Treatment–resistant END start-ver=1.4 cd-journal=joma no-vol=150 cd-vols= no-issue=3 article-no= start-page=730 end-page=741 dt-received= dt-revised= dt-accepted= dt-pub-year=2008 dt-pub=20080528 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Angiotensin II type 2 receptors facilitate reinnervation of phenol-lesioned vascular calcitonin gene-related peptide (CGRP)-containing nerves in rat mesenteric arteries en-subtitle= kn-subtitle= en-abstract= kn-abstract=

The present study was designed to investigate involvement of angiotensin (Ang) II type 2 receptors (AT2 receptors) in restoration of perivascular nerve innervation injured by topical phenol treatment. Male Wistar rats underwent in vivo topical application of 10% phenol around the superior mesenteric artery. After phenol treatment, animals were subjected to immunohistochemistry of the third branch of small arteries, Western blot analysis of AT2 receptor protein expression in dorsal root ganglia (DRG) and studies of mesenteric neurogenic vasoresponsiveness. Ang II (750 ng/kg/day), nerve growth factor (NGF; 20 μg/kg/day) and PD123,319 (AT2 receptor antagonist; 10 mg/kg/day) were intraperitoneally administered for 7 days using osmotic mini-pumps immediately after topical phenol treatment. Losartan (AT1 receptor antagonist) was administered in drinking water (0.025%). Phenol treatment markedly reduced densities of both calcitonin gene-related peptide (CGRP)-like immunoreactivity (LI)- and neuropeptide Y (NPY)-LI-containing fibers. NGF restored densities of both nerve fibers to the Sham control level. Coadministration of Ang II and losartan significantly increased the density of CGRP-LI-fibers but not NPY-LI-fibers compared with saline control. The increase of the density of CGRP-LI-fibers by coadministration of Ang II and losartan was suppressed by adding PD123,319. Coadministration of Ang II and losartan ameliorated reduction of CGRP nerve-mediated vasodilation of perfused mesenteric arteries caused by phenol treatment. The AT2 receptor protein expression detected in DRG was markedly increased by NGF. These results suggest that selective stimulation of AT2 receptors by Ang II facilitates reinnervation of mesenteric perivascular CGRP-containing nerves injured by topical phenol application in the rat.

en-copyright= kn-copyright= en-aut-name=HobaraNarumi en-aut-sei=Hobara en-aut-mei=Narumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=GodaMitsuhiro en-aut-sei=Goda en-aut-mei=Mitsuhiro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=YoshidaNamika en-aut-sei=Yoshida en-aut-mei=Namika kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TakatoriShingo en-aut-sei=Takatori en-aut-mei=Shingo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=MioMitsunobu en-aut-sei=Mio en-aut-mei=Mitsunobu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KawasakiHiromu en-aut-sei=Kawasaki en-aut-mei=Hiromu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil= kn-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University affil-num=2 en-affil= kn-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University affil-num=3 en-affil= kn-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University affil-num=4 en-affil= kn-affil=Shujitsu University School of Pharmacy affil-num=5 en-affil= kn-affil=Department of Pharmaceutical Care and Health Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University affil-num=6 en-affil= kn-affil=Shujitsu University School of Pharmacy affil-num=7 en-affil= kn-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University en-keyword=Angiotensin II type 2 receptors kn-keyword=Angiotensin II type 2 receptors en-keyword=Phenol-induced perivascular nerve injury kn-keyword=Phenol-induced perivascular nerve injury en-keyword=Calcitonin gene-related peptide-containing nerves kn-keyword=Calcitonin gene-related peptide-containing nerves en-keyword=Neuropeptide Y-containing nerves kn-keyword=Neuropeptide Y-containing nerves en-keyword=Neurotrophic kn-keyword=Neurotrophic en-keyword=Rat mesenteric artery kn-keyword=Rat mesenteric artery END start-ver=1.4 cd-journal=joma no-vol=61 cd-vols= no-issue=6 article-no= start-page=311 end-page=317 dt-received= dt-revised= dt-accepted= dt-pub-year=2007 dt-pub=200712 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=The Influence of Hyperactivity of the Hypothalamic-pituitary-adrenal Axis and Hyperglycemia on the 5-HT2A Receptor-mediated Wet-dog Shake Responses in Rats en-subtitle= kn-subtitle= en-abstract= kn-abstract=

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis induces hyperglycemia and serotonin (5-HT)2A receptor supersensitivity. In the present study, to investigate the effect of hyperglycemia on the function of 5-HT2A receptors, we compared the 5-HT2A receptor-mediated wet-dog shake responses in rats treated with adrenocorticotropic hormone (ACTH), dexamethasone and streptozotocin. ACTH (100 μg/rat per day, s.c.), dexamethasone (1 mg/kg per day, s.c.) and streptozotocin (60 mg/kg, i.p.) produced significant hyperglycemia at 14 days after the start of these treatments, and the hyperglycemia was most pronounced in the streptozotocin-treated rats. The wet-dog shake responses induced by (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2A receptor agonist, were significantly enhanced at 14 days after repeated treatment with ACTH and dexamethasone. However, streptozotocin-induced diabetes had no effect on the wet-dog shake responses. The results of the present study suggest that hyperglycemia is not strongly associated with the enhanced susceptibility of 5-HT2A receptors under the condition of hyperactivity of the HPA axis.

en-copyright= kn-copyright= en-aut-name=UmedaYuichi en-aut-sei=Umeda en-aut-mei=Yuichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=AmanoManabu en-aut-sei=Amano en-aut-mei=Manabu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=SuemaruKatsuya en-aut-sei=Suemaru en-aut-mei=Katsuya kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=YamaguchiTakumi en-aut-sei=Yamaguchi en-aut-mei=Takumi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=KawasakiHiromu en-aut-sei=Kawasaki en-aut-mei=Hiromu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=ArakiHiroaki en-aut-sei=Araki en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= affil-num=1 en-affil= kn-affil=Ehime University affil-num=2 en-affil= kn-affil=Okayama University affil-num=3 en-affil= kn-affil=Ehime University affil-num=4 en-affil= kn-affil=Ehime University affil-num=5 en-affil= kn-affil=Okayama University Hospital affil-num=6 en-affil= kn-affil=Okayama University Hospital affil-num=7 en-affil= kn-affil=Okayama University affil-num=8 en-affil= kn-affil=Ehime University en-keyword=hyperglycemia kn-keyword=hyperglycemia en-keyword=ACTH kn-keyword=ACTH en-keyword=dexamethasone kn-keyword=dexamethasone en-keyword=streptozotocin kn-keyword=streptozotocin en-keyword=5-HT2A receptor kn-keyword=5-HT2A receptor END start-ver=1.4 cd-journal=joma no-vol=58 cd-vols= no-issue=6 article-no= start-page=271 end-page=274 dt-received= dt-revised= dt-accepted= dt-pub-year=2004 dt-pub=200412 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Influence of imipramine on the duration of immobility in chronic forced-swim-stressed rats. en-subtitle= kn-subtitle= en-abstract= kn-abstract=

We studied the influence of imipramine on the duration of immobility in chronic forced-swim-stressed rats. Both single and chronic administration of imipramine potently shortened immobility in naive rats during forced-swim testing. However, chronic, 14-day forced-swim stress testing blocked the immobility-decreasing effect induced by a single administration of imipramine. When imipramine was administered for 14 days concurrently with forced-swim stress testing, immobility was shortened significantly. From the viewpoint of imipramine's effect, these findings suggest that chronic forced-swim stress testing in rats may be an effective animal model for depression.

en-copyright= kn-copyright= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=ArakiHiroaki en-aut-sei=Araki en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=NagataniTadashi en-aut-sei=Nagatani en-aut-mei=Tadashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=TakaoKatsuyuki en-aut-sei=Takao en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=ShibataKazuhiko en-aut-sei=Shibata en-aut-mei=Kazuhiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=Okayama University affil-num=2 en-affil= kn-affil=Ehime University Hospital affil-num=3 en-affil= kn-affil=Asahi Kasei Co. affil-num=4 en-affil= kn-affil=Asahi Kasei Co. affil-num=5 en-affil= kn-affil=Okayama University affil-num=6 en-affil= kn-affil=Okayama University en-keyword=stress kn-keyword=stress en-keyword=depression kn-keyword=depression en-keyword=imipramine kn-keyword=imipramine en-keyword=forced-swim test kn-keyword=forced-swim test en-keyword=animal model kn-keyword=animal model END start-ver=1.4 cd-journal=joma no-vol=62 cd-vols= no-issue=4 article-no= start-page=227 end-page=233 dt-received= dt-revised= dt-accepted= dt-pub-year=2008 dt-pub=200808 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Motivational Effects of Nicotine as Measured by the Runway Method Using Priming Stimulation of Intracranial Self-stimulation Behavior en-subtitle= kn-subtitle= en-abstract= kn-abstract=

It is well known that priming stimulation promotes the motivational effects of intracranial self-stimulation(ICSS) behavior. An experimental methodology using the runway method could separately study the reward and motivational effects of ICSS behavior. In the present study, we examined the motivational effect of nicotine as measured by the runway method using priming stimulation of ICSS behavior. Electrodes were implanted chronically into the medial forebrain bundle (MFB) in rats. A lever for stimulation of the MFB was set on the opposite side of the start box in the apparatus, and rats were trained to get a reward stimulation (50-200 microA, 0.2 ms, 60 Hz) of MFB when the goal lever was pressed. After the rats were trained to press the lever, a priming stimulation of the MFB was performed. After receiving the priming stimulation, rats were placed at the start box of the runway apparatus, and the running time duration until the goal lever was pressed was measured. Subcutaneous injection of nicotine at a dose of 0.2mg/kg produced an increase in running speed to obtain the reward stimulation, and priming stimulation facilitated the motivational effect to obtain the electrical brain stimulation reward in the rats. These results suggest that nicotine significantly enhanced the motivational effect on ICSS behavior as determined using the runway method. The runway method using priming stimulation of ICSS behavior may become the new experimental methodology with which to measure the motivational effect of some drugs.

en-copyright= kn-copyright= en-aut-name=SagaraHidenori en-aut-sei=Sagara en-aut-mei=Hidenori kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=EsumiSatoru en-aut-sei=Esumi en-aut-mei=Satoru kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=ArakiHiroaki en-aut-sei=Araki en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=2 en-affil= kn-affil=Department of Pharmaceutical Care and Health Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences affil-num=3 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=4 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital affil-num=5 en-affil= kn-affil=Division of Pharmacy, Ehime University Hospital affil-num=6 en-affil= kn-affil=Department of Pharmacy, Okayama University Hospital en-keyword=intracranial self-stimulation kn-keyword=intracranial self-stimulation en-keyword=runway kn-keyword=runway en-keyword=nicotine kn-keyword=nicotine en-keyword=priming stimulation kn-keyword=priming stimulation en-keyword=motivational effect kn-keyword=motivational effect END start-ver=1.4 cd-journal=joma no-vol=74 cd-vols= no-issue= article-no= start-page=51 end-page=56 dt-received= dt-revised= dt-accepted= dt-pub-year=2004 dt-pub=20040201 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=気管支喘息患者におけるモンテルカストの有用性についての検討　－テオフイリンとモンテルカスト併用の影響を中心に－ en-subtitle= kn-subtitle= en-abstract= kn-abstract=新規ロイコトリエン（LT）受容体桔抗薬であるモンテルカスト服用によるテオフイリン服用患者の処方動向，臨床検査値ならびに患者の服用に対する意識について検討を行った。 その結果，テオフイリン服用患者177名の内，51％がLT受容体抵抗薬を併用しており，併用率はモンテルカストが最も多く，プランルカスとザフィルルカストの順であった。また，プランルカストからモンテルカストに変更された症例が多かった。臨床検査値はモンテルカスト服用により血中好酸球数の減少作用が認められた。肝機能検査値（AST・ALT・ALP）は影響しなかった。テオフイリン服用量はモンテルカスト併用服用により減量され，それに伴い血中濃度も低下した。しかしながら，血中濃度／投与量比は影響しなかったことより，モンテルカストはテオフイリンクリアランスに影響しないと考えられる。モンテルカストヘの変更により，患者の服薬コンプライアンスは良好に維持され，自覚する副作用の発現は認められ なかった。以上の結果，テオフイリン服用患者へのモンテルカスト併用投与は良好な服薬コンプライアンスを維持させ，さらにテオフイリンの体内動態に影響を及ぼすことなく，テオフイリンの投与量を減少させ，患者のQOLの向上につながると考えられる。 en-copyright= kn-copyright= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=1 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=三宅悟 kn-aut-sei=三宅 kn-aut-mei=悟 aut-affil-num=2 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=横山紀子 kn-aut-sei=横山 kn-aut-mei=紀子 aut-affil-num=3 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=川上英治 kn-aut-sei=川上 kn-aut-mei=英治 aut-affil-num=4 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=荒木博陽 kn-aut-sei=荒木 kn-aut-mei=博陽 aut-affil-num=5 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=柴田和彦 kn-aut-sei=柴田 kn-aut-mei=和彦 aut-affil-num=6 ORCID= en-aut-name= en-aut-sei= en-aut-mei= kn-aut-name=五味田裕 kn-aut-sei=五味田 kn-aut-mei=裕 aut-affil-num=7 ORCID= en-aut-name=MitsunobuFumihiro en-aut-sei=Mitsunobu en-aut-mei=Fumihiro kn-aut-name=光延文裕 kn-aut-sei=光延 kn-aut-mei=文裕 aut-affil-num=8 ORCID= en-aut-name=TanizakiYoshiro en-aut-sei=Tanizaki en-aut-mei=Yoshiro kn-aut-name=谷崎勝朗 kn-aut-sei=谷崎 kn-aut-mei=勝朗 aut-affil-num=9 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 三朝医療センター 薬剤室 affil-num=2 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 三朝医療センター 薬剤室 affil-num=3 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 薬剤部 affil-num=4 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 三朝医療センター 薬剤室 affil-num=5 en-affil= kn-affil= affil-num=6 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 薬剤部 affil-num=7 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 薬剤部 affil-num=8 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 三朝医療センター 内科 affil-num=9 en-affil= kn-affil=岡山大学医学部・歯学部附属病院 三朝医療センター 内科 en-keyword=モンテルカスト kn-keyword=モンテルカスト en-keyword=テオフイリン kn-keyword=テオフイリン en-keyword=服薬コンプライアンス kn-keyword=服薬コンプライアンス en-keyword=血中濃度 kn-keyword=血中濃度 END start-ver=1.4 cd-journal=joma no-vol=119 cd-vols= no-issue=1 article-no= start-page=83 end-page=85 dt-received= dt-revised= dt-accepted= dt-pub-year=2007 dt-pub=20070501 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction (9. effect of smoking) kn-title=薬物相互作用 (9―喫煙と薬の相互作用) en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=SagaraHidenori en-aut-sei=Sagara en-aut-mei=Hidenori kn-aut-name=相良英憲 kn-aut-sei=相良 kn-aut-mei=英憲 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=3 ORCID= en-aut-name=GomitaYutaka en-aut-sei=Gomita en-aut-mei=Yutaka kn-aut-name=五味田裕 kn-aut-sei=五味田 kn-aut-mei=裕 aut-affil-num=4 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　薬剤部 affil-num=2 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科 医薬管理学 affil-num=3 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　薬剤部 affil-num=4 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　薬剤部 END start-ver=1.4 cd-journal=joma no-vol=120 cd-vols= no-issue=1 article-no= start-page=91 end-page=94 dt-received= dt-revised= dt-accepted= dt-pub-year=2008 dt-pub=20080501 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Drug interaction(12. Combination with benzodiazepine hypnotics) kn-title=薬物相互作用(12―ベンゾジアゼピン系睡眠薬の薬物相互作用） en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=ShinomiyaKazuaki en-aut-sei=Shinomiya en-aut-mei=Kazuaki kn-aut-name=四宮一昭 kn-aut-sei=四宮 kn-aut-mei=一昭 aut-affil-num=1 ORCID= en-aut-name=KitamuraYoshihisa en-aut-sei=Kitamura en-aut-mei=Yoshihisa kn-aut-name=北村佳久 kn-aut-sei=北村 kn-aut-mei=佳久 aut-affil-num=2 ORCID= en-aut-name=UeshimaSatoshi en-aut-sei=Ueshima en-aut-mei=Satoshi kn-aut-name=上島智 kn-aut-sei=上島 kn-aut-mei=智 aut-affil-num=3 ORCID= en-aut-name=SatohTomoaki en-aut-sei=Satoh en-aut-mei=Tomoaki kn-aut-name=佐藤智昭 kn-aut-sei=佐藤 kn-aut-mei=智昭 aut-affil-num=4 ORCID= en-aut-name=SendoToshiaki en-aut-sei=Sendo en-aut-mei=Toshiaki kn-aut-name=千堂年昭 kn-aut-sei=千堂 kn-aut-mei=年昭 aut-affil-num=5 ORCID= affil-num=1 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　医薬管理学 affil-num=2 en-affil= kn-affil=岡山大学大学院医歯薬学総合研究科　医薬管理学 affil-num=3 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　薬剤部 affil-num=4 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　薬剤部 affil-num=5 en-affil= kn-affil=岡山大学医学部・歯学部附属病院　薬剤部 END